BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

958 related articles for article (PubMed ID: 16712662)

  • 21. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line.
    Jeong H; Kim YR; Kim KN; Choe JG; Chung JK; Kim MK
    Nucl Med Biol; 2006 Oct; 33(7):875-82. PubMed ID: 17045167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells.
    Kim KI; Kang JH; Chung JK; Lee YJ; Jeong JM; Lee DS; Lee MC
    J Nucl Med; 2007 Sep; 48(9):1553-61. PubMed ID: 17704247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients.
    Schlumberger M; Lacroix L; Russo D; Filetti S; Bidart JM
    Nat Clin Pract Endocrinol Metab; 2007 Mar; 3(3):260-9. PubMed ID: 17315034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome.
    Walter MA; Christ-Crain M; Eckard B; Schindler C; Nitzsche EU; Müller-Brand J; Müller B
    Eur J Clin Invest; 2004 May; 34(5):365-70. PubMed ID: 15147334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioiodide uptake and sodium iodide symporter expression in breast carcinoma.
    Damle AA; Narkar AA; Badwe RA
    Indian J Exp Biol; 2011 Jun; 49(6):416-22. PubMed ID: 21702220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishment and characterization of a breast cancer cell line expressing Na+/I- symporters for radioiodide concentrator gene therapy.
    Nakamoto Y; Saga T; Misaki T; Kobayashi H; Sato N; Ishimori T; Kosugi S; Sakahara H; Konishi J
    J Nucl Med; 2000 Nov; 41(11):1898-904. PubMed ID: 11079502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive role of nontumoral sodium iodide symporter activity and preoperative thyroid characteristics in remission process of thyroid cancer patients.
    Yildirim-Poyraz N; Yazgan A; Ozdemir E; Gozalan A; Keskin M; Ersoy R; Turkolmez S; Cakir B
    Ann Nucl Med; 2014 Aug; 28(7):623-31. PubMed ID: 24823701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression.
    Cengic N; Baker CH; Schütz M; Göke B; Morris JC; Spitzweg C
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4457-64. PubMed ID: 15941870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma.
    Pluijmen MJ; Eustatia-Rutten C; Goslings BM; Stokkel MP; Arias AM; Diamant M; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):428-35. PubMed ID: 12641625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
    Kogai T; Taki K; Brent GA
    Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
    Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
    Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The rat sodium iodide symporter gene permits more effective radioisotope concentration than the human sodium iodide symporter gene in human and rodent cancer cells.
    Heltemes LM; Hagan CR; Mitrofanova EE; Panchal RG; Guo J; Link CJ
    Cancer Gene Ther; 2003 Jan; 10(1):14-22. PubMed ID: 12489024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene therapy with sodium/iodide symporter in hepatocarcinoma.
    Haberkorn U
    Exp Clin Endocrinol Diabetes; 2001; 109(1):60-2. PubMed ID: 11573143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
    Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of I131 ablation therapy using different doses as determined by postoperative thyroid scan uptake in patients with differentiated thyroid cancer.
    Zidan J; Hefer E; Iosilevski G; Drumea K; Stein ME; Kuten A; Israel O
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1330-6. PubMed ID: 15275717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lithium as an adjuvant in the radioiodine therapy of thyroid cancer].
    Schraube P; Kimmig B; zum Winkel K
    Nuklearmedizin; 1984 Jun; 23(3):151-4. PubMed ID: 6435095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas.
    Cho JY; Shen DH; Yang W; Williams B; Buckwalter TL; La Perle KM; Hinkle G; Pozderac R; Kloos R; Nagaraja HN; Barth RF; Jhiang SM
    Gene Ther; 2002 Sep; 9(17):1139-45. PubMed ID: 12170377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
    Hoftijzer H; Heemstra KA; Morreau H; Stokkel MP; Corssmit EP; Gelderblom H; Weijers K; Pereira AM; Huijberts M; Kapiteijn E; Romijn JA; Smit JW
    Eur J Endocrinol; 2009 Dec; 161(6):923-31. PubMed ID: 19773371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
    Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
    Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.